A late-stage biopharmaceutical company dedicated to metabolic and chronic liver diseases is developing an in vitro diagnostic (IVD) test for NASH at-risk patients. The test integrates four independent biomarkers – miR-34a-5p, A2M, YKL-40, and HbA1c. The output is a 0-10 score with threshold values, identifying patients with low risk or high risk of developing NASH.
The main objective of this study is to evaluate the physiological stability of these biomarkers between the fed and fasting state in patients with the target condition (NAFLD) over a 30-day period.
Discover how our team of experts helped this biopharmaceutical company to reach its goals
Case Study – A blood-based biomarker panel for non-invasive diagnosis of non-alcoholic steatohepatitis: a multi-centre prospective and validation study
Reach out to our experts and discover how we can help transform your research to advance healthContact Us